Skip to main content

Table 2 Propensity matching, logistic regression, and odds ratio estimate

From: Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19

 

total (n)

survived (n/%)

p-value

odds

CI (2.5%)

CI (97.5%)

CP-group

406

320/79

< 0.001

2.314

1.783

3.029

nCP-group

1218

751/62

N/A

N/A

N/A

N/A

early CP-group (up to three days)

100

87/87

0.023

2.097

1.139

4.132

late CP-group (more than four days)

306

233/76

< 0.001

 N/A

 N/A

 N/A

nCP-group

1218

751/62

N/A

 0.504  

 0.376

 0.668

  1. CP-group, cohort receiving convalescent plasma; nCP, control group without administration of convalescent plasma; N/A, not applicable
Back to article page

Virology Journal

ISSN: 1743-422X